BMS' Opdivo Is Too Expensive, Says NICE
Executive Summary
NICE has again said no to Bristol-Myers Squibb's Opdivo, this time for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults already treated with chemotherapy. The company had suggested different pricing proposals to try and make the drug more cost-effective, but it may fare better if it focuses on certain patient populations.
You may also be interested in...
UK's NICE OKs BMS' Opdivo-Yervoy Combo In Advanced Skin Cancer
The UK HTA has recommended Bristol-Myers Squibb's combination therapy of Opdivo and Yervoy to treat patients on the publicly-funded NHS with advanced skin cancer, marking one of the quickest decisions ever from NICE and issued only weeks after the combo was licensed by the EU's European Commission.
NICE Knockback For BMS Immunotherapy Opdivo In Lung Cancer
Bristol-Myers Squibb Co.'s immunotherapy Opdivo (nivolumab) is not cost-effective and should not be provided for NHS patients with lung cancer in England and Wales, according to draft guidance from the health technology assessment body NICE. BMS had offered a confidential discounting scheme to reduce the cost below its list price of £5,200 per month (for a patient weighing 73kg), but this failed to sway the National Institute for Health and Care Excellence.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.